FINNENCE ▪ THE WIRE FILE
THE WIRE · № 57252
Company■ Unclear/unknown
New Phase 3 trial: A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy — Novartis
KINDCompany
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-30 12:00 UTC
LAST UPDATE2026-09-30 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Novartis Phase 3 combines zigakibart and atrasentan in IgA nephropathy, a pipeline expansion not yet recruiting.
Novartis advances IgA nephropathy combination
CATALYST TO WATCH
Enrollment and interim results
MAIN RISK
Combination safety and efficacy unproven
FULL DISPATCH
Sponsor: Novartis; Status: Not Yet Recruiting; Conditions: IgA Nephropathy (IgAN); Interventions: zigakibart, atrasentan, Placebo; Enrollment: 340 (estimated); First posted: 2026-09-30; NCT: NCT07850752
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Phase 3 trial: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease — Boehringer Ingelheim2026-09-30 12:00 UTC
New Phase 3 trial: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease — Boehringer Ingelheim2026-09-30 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight — Boehringer Ingelheim2026-09-30 12:00 UTC
New Phase 3 trial: SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight — Boehringer Ingelheim2026-09-30 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury — IBSA Institut Biochimique SA2026-09-30 12:00 UTC
Phase 3 results posted: Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury — IBSA Institut Biochimique SA2026-09-30 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy — Teva Pharmaceuticals USA2026-09-30 12:00 UTC
Phase 3 results posted: Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy — Teva Pharmaceuticals USA2026-09-30 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases — Takeda2026-09-30 12:00 UTC
Phase 3 results posted: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases — Takeda2026-09-30 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.